Shares of Cynapsus Therapeutics Inc. (NASDAQ:CYNA) saw strong trading volume on Friday . 588,291 shares changed hands during trading, an increase of 27% from the previous session’s volume of 462,602 shares.The stock last traded at $39.69 and had previously closed at $39.70.

Several equities research analysts have weighed in on the company. BMO Capital Markets restated a “buy” rating on shares of Cynapsus Therapeutics in a research note on Thursday, May 12th. Janney Montgomery Scott cut Cynapsus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday. Finally, Noble Financial restated a “buy” rating and set a $50.00 target price on shares of Cynapsus Therapeutics in a research note on Tuesday.

The company’s 50-day moving average price is $18.69 and its 200 day moving average price is $14.83. The stock’s market capitalization is $492.47 million.

Cynapsus Therapeutics (NASDAQ:CYNA) last posted its quarterly earnings results on Thursday, August 11th. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $1.60. On average, equities analysts predict that Cynapsus Therapeutics Inc. will post ($3.15) earnings per share for the current fiscal year.

Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.